Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT02960607
What this trial is testing

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Chinese Academy of Medical Sciences 25
Early research (Phase 1)UnknownNCT06362980
What this trial is testing

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Who this might be right for
NSCLC
National Cancer Center, China 20
Early research (Phase 1)Study completedNCT03452150
What this trial is testing

D-0316 First Time in Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung Cancer
InventisBio Co., Ltd 84
Testing effectiveness (Phase 2)UnknownNCT04646824
What this trial is testing

Almonertinib With Chemotherapy in mEGFR NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Tianjin Medical University Cancer Institute and Hospital 10
Not applicableLooking for participantsNCT06102928
What this trial is testing

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University 30
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Large-scale testing (Phase 3)Study completedNCT01887886
What this trial is testing

Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 10
Large-scale testing (Phase 3)Study completedNCT03653546
What this trial is testing

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationBrain Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 492
Not applicableNot Yet RecruitingNCT05698264
What this trial is testing

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationImmune Checkpoint Inhibitor
Nir Peled 50
Large-scale testing (Phase 3)Active Not RecruitingNCT02511106
What this trial is testing

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Who this might be right for
Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca 682
Testing effectiveness (Phase 2)Looking for participantsNCT04486833
What this trial is testing

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Who this might be right for
Carcinoma, Non-Small Cell Lung
Genprex, Inc. 158
Testing effectiveness (Phase 2)UnknownNCT03151161
What this trial is testing

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Lung, Carcinoma
Sun Yat-sen University 118
Not applicableUnknownNCT01100827
What this trial is testing

A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
NSCLC
National University Hospital, Singapore
Testing effectiveness (Phase 2)UnknownNCT03062800
What this trial is testing

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Who this might be right for
Advanced Nsclc
Qilu Hospital of Shandong University 232
Testing effectiveness (Phase 2)UnknownNCT03341494
What this trial is testing

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Who this might be right for
NSCLC Stage IVChemotherapy Effect
Fujian Cancer Hospital 128
Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Large-scale testing (Phase 3)Looking for participantsNCT04853342
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non-small Cell Lung Carcinoma
Allist Pharmaceuticals, Inc. 318
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Not applicableNo Longer AvailableNCT02547675
What this trial is testing

Rociletinib (CO-1686) USA Expanded Access Program

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc.
Next Page